SIGA Technologies Inc (OQ:SIGA)

Apr 01, 2024 04:05 pm ET
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical...
Mar 25, 2024 07:30 am ET
SIGA Names Larry Miller General Counsel
SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of...
Mar 21, 2024 09:31 am ET
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
NEW YORK, March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HQY, PCRX, IPG, SIGA, and SRTS.
Mar 12, 2024 04:05 pm ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product revenues...
Mar 12, 2024 07:30 am ET
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents an increase of...
Mar 05, 2024 07:30 am ET
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024....
Jan 22, 2024 07:30 am ET
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27,...
Nov 07, 2023 04:05 pm ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine...
Oct 26, 2023 07:30 am ET
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023....
Oct 23, 2023 08:00 am ET
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission’s DG HERA (Health Emergency Preparedness and Response Authority)...
Sep 06, 2023 07:30 am ET
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He...
Aug 08, 2023 04:05 pm ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2023. “SIGA’s second quarter financial results reflect the continuation of...
Jul 27, 2023 04:45 pm ET
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of...
Jul 27, 2023 07:30 am ET
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 8th, 2023....
Jun 27, 2023 04:05 pm ET
SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that SIGA CEO Phil Gomez, PhD, will present an overview of the role of therapeutics in global planning...
May 04, 2023 04:05 pm ET
SIGA Reports Financial Results for Three Months Ended March 31, 2023
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2023. “First quarter product revenues primarily reflect the sale of oral TPOXX to the...
May 04, 2023 07:30 am ET
SIGA Declares Special Cash Dividend of $0.45 Per Share
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company. The special cash dividend...
Apr 27, 2023 07:30 am ET
SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 4th, 2023. Participating...
Mar 02, 2023 04:05 pm ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2022. “In 2022, SIGA had approximately $111 million in revenue including...
Feb 23, 2023 07:30 am ET
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 2nd, 2023....
Jan 17, 2023 07:30 am ET
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Phil Gomez, PhD, Chief Executive Officer of SIGA, has announced his intention to retire as CEO in...
Nov 03, 2022 04:05 pm ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2022. “With significant international sales, our third quarter financial...
Oct 27, 2022 04:15 pm ET
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 2022....
Oct 12, 2022 04:05 pm ET
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of...
Sep 29, 2022 07:30 am ET
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to...
Sep 26, 2022 10:07 am ET
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced receipt of approximately $16 million of international procurement orders for oral TPOXX® (tecovirimat)...
Aug 09, 2022 07:30 am ET
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the...
Aug 04, 2022 04:05 pm ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2022. “SIGA’s second quarter financial results reflect the first sales of oral...
Aug 01, 2022 09:31 am ET
Thinking about buying stock in Toughbuilt Industries, EVO Payments, SIGA Technologies, Solo Brands, or Alliance Resource Partners?
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, EVOP, SIGA, DTC, and ARLP.
Jul 29, 2022 10:45 am ET
Thinking about buying stock in Intel Corp, Thermogenesis, SIGA Technologies, Tonix Pharmaceuticals, or Sunrun?
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, THMO, SIGA, TNXP, and RUN.
Jul 28, 2022 04:15 pm ET
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 4th, 2022....
Jul 27, 2022 10:40 am ET
Thinking about buying stock in Shopify, Obseva SA, Vistagen Therapeutics, SIGA Technologies, or Exela Technologies?
NEW YORK, July 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SHOP, OBSV, VTGN, SIGA, and XELA.
Jul 25, 2022 11:35 am ET
Thinking about buying stock in Snap, SIGA Technologies, Sundial Growers, General Electric, or Marathon Digital?
NEW YORK, July 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNAP, SIGA, SNDL, GE, and MARA.
Jul 15, 2022 07:30 am ET
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® (tecovirimat) available for use with...
Jul 12, 2022 04:15 pm ET
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX® (tecovirimat), including approximately...
Jul 08, 2022 07:30 am ET
SIGA Technologies Receives Approval from UK for Tecovirimat
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the...
Jun 23, 2022 10:55 am ET
Thinking about buying stock in Revlon, CNS Pharmaceuticals, SIGA Technologies, Freeport-McMoRan, or Kirkland's?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for REV, CNSP, SIGA, FCX, and KIRK.
Jun 23, 2022 08:00 am ET
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for...
Jun 22, 2022 10:13 am ET
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its Chief Executive Officer, Phil Gomez, and Chief Scientific Officer, Dennis Hruby, will be...
May 27, 2022 09:31 am ET
Thinking about buying stock in Concert Pharmaceuticals, PMV Pharmaceuticals, Allbirds, SIGA Technologies, or Elevation Oncology?
NEW YORK, May 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNCE, PMVP, BIRD, SIGA, and ELEV.
May 23, 2022 11:00 am ET
BioMed Stocks On the Move: GeoVax Labs, Nova Mentis, SIGA and PharmaDrug; Life Sciences Leaders Report Latest Advances in Antiviral Vaccines, and Novel Therapeutics for Oncology, Glaucoma and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: SIGA Technologies (NASDAQ: SIGA), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), GeoVax Labs (NASDAQ:...
May 23, 2022 08:30 am ET
Thinking about buying stock in SIGA Technologies, Geovax Labs, Inovio Pharmaceuticals, ImmunoGen, or Emergent Biosolutions?
NEW YORK, May 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SIGA, GOVX, INO, IMGN, and EBS.
May 19, 2022 10:55 am ET
Thinking about buying stock in Neurometrix, Grab, SIGA Technologies, Inovio Pharmaceuticals, or Roblox?
NEW YORK, May 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NURO, GRAB, SIGA, INO, and RBLX.
May 19, 2022 07:30 am ET
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for...
May 12, 2022 04:05 pm ET
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a contract to SIGA for the procurement of up to...
May 05, 2022 04:05 pm ET
SIGA Reports Financial Results for Three Months Ended March 31, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2022. “SIGA’s first quarter financial results are highlighted by the first sale of the...
May 05, 2022 07:30 am ET
SIGA Declares Special Dividend of $0.45 Per Share
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company. The special dividend is payable...
Apr 28, 2022 04:05 pm ET
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 5th, 2022. Participating...
Mar 03, 2022 04:05 pm ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2021. “SIGA’s fourth quarter and annual financial results are...
Mar 02, 2022 07:30 am ET
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has initiated the clinical program to support a U.S. Food and Drug Administration (FDA) label...
Feb 24, 2022 10:27 am ET
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 3rd, 2022....
Jan 25, 2022 07:30 am ET
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Bioarchitech, a United Kingdom-based biotech company...
Jan 18, 2022 07:30 am ET
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group’s Open House Event, scheduled to take place virtually this...
Jan 10, 2022 07:30 am ET
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency (EMA) approved SIGA’s Marketing Authorisation Application (MAA) for...
Dec 01, 2021 09:55 am ET
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Health Canada has approved oral TPOXX® (tecovirimat) as an extraordinary use new drug....
Nov 16, 2021 08:30 am ET
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) published their...
Nov 04, 2021 04:05 pm ET
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
IGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2021. “SIGA’s financial results for the first nine months of 2021 include...
Oct 28, 2021 04:15 pm ET
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 4th, 2021....
Sep 13, 2021 07:30 am ET
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its 75A50118C00019 (19C) contract with Biomedical Advanced Research and Development...
Sep 07, 2021 01:16 pm ET
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore,...
Aug 05, 2021 04:15 pm ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2021. “SIGA’s second quarter financial results show a steady continuing...
Jul 29, 2021 04:15 pm ET
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 5th, 2021....
Jul 29, 2021 03:30 am ET
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a collaboration with Oxford University in the United Kingdom (UK) to provide...
Jun 30, 2021 07:30 am ET
SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it provided TPOXX® (tecovirimat) to Liverpool University Hospitals NHS Foundation Trust, in the...
May 06, 2021 04:05 pm ET
SIGA Reports Financial Results for Three Months Ended March 31, 2021
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2021. “SIGA’s first quarter financial results reflect a positive general trend with...
May 04, 2021 07:30 am ET
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the...
Apr 29, 2021 08:00 am ET
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 6, 2021. Participating...
Mar 23, 2021 08:00 am ET
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health...
Mar 04, 2021 04:05 pm ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2020. “SIGA’s fourth quarter and annual financial results are highlighted...
Feb 26, 2021 07:30 am ET
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Jan 13, 2021 04:45 pm ET
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health Agency of Canada (PHAC) has awarded a contract to Meridian Medical Technologies,...
Nov 12, 2020 04:05 pm ET
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the...
Nov 05, 2020 04:05 pm ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported financial results for the three and nine months ended September 30, 2020. “SIGA’s third quarter was...
Oct 29, 2020 07:30 am ET
SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Oct 08, 2020 07:30 am ET
SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health Agency of Canada (PHAC) has issued an advanced contract award notice (ACAN),...
Sep 10, 2020 08:30 am ET
SIGA to Participate at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in a fireside chat at the...
Aug 31, 2020 07:30 am ET
Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, SIGA’s Chief Scientific Officer, has been named a recipient of the 2021 American...
Aug 06, 2020 04:05 pm ET
SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported financial results for the three and six months ended June 30, 2020. “SIGA’s successful second quarter...
Jul 30, 2020 04:01 pm ET
SIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Jul 30, 2020 07:30 am ET
SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA)...
Jun 25, 2020 04:05 pm ET
SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS)....
Jun 15, 2020 07:30 am ET
SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX® 
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical,...
Jun 01, 2020 05:00 pm ET
SIGA Changes its 2020 Annual Meeting of Stockholders to Virtual Format
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only...
Jun 01, 2020 09:01 am ET
SIGA Technologies Announces First International Delivery of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced its first international delivery of TPOXX® (tecovirimat), with 2,500 courses delivered to the Canadian...
May 06, 2020 04:05 pm ET
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported financial results for the three months ended March 31, 2020. First Quarter 2020 Financial Results...
Apr 29, 2020 04:30 pm ET
SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA)...
Apr 29, 2020 07:30 am ET
SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Apr 03, 2020 10:15 am ET
SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has awarded a contract to Meridian Medical...
Mar 05, 2020 04:05 pm ET
SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported 2019 full year financial results and announced product delivery expectations for oral TPOXX® under the...
Mar 02, 2020 04:30 pm ET
SIGA Announces Collaboration with Turnstone Biologics
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX® (tecovirimat) in...
Feb 20, 2020 04:59 pm ET
SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Dec 05, 2019 12:10 pm ET
SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice...
Nov 18, 2019 07:30 am ET
SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice...
Oct 21, 2019 07:30 am ET
SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats...
Oct 03, 2019 07:30 am ET
SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020   
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has reached concurrence with the US Food and Drug Administration (FDA) that no further clinical...
Sep 26, 2019 07:30 am ET
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global...
Sep 25, 2019 07:30 am ET
SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the 13th...
Aug 28, 2019 07:30 am ET
SIGA to Present at the 14th Annual Wells Fargo Securities Healthcare Conference on September 5, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in an analyst-led fireside...
Jul 08, 2019 07:30 am ET
SIGA Awarded Department of Defense Contract to Develop Expanded Indication for TPOXX® as Post-Exposure Prophylactic for Smallpox
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has been awarded a multi-year contract from the United States Department of Defense (DoD) to...
Jun 18, 2019 07:30 am ET
SIGA Technologies CEO to Speak at NCT Europe on June 27, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats...
Jun 11, 2019 07:30 am ET
SIGA Technologies to Host Business Update Webcast on June 18, 2019
SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Jun 03, 2019 07:30 am ET
SIGA Announces TPOXX® Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an international promotion agreement with Meridian Medical Technologies, Inc....
May 20, 2019 04:30 pm ET
SIGA Announces Exercise of Option for the Purchase of Raw Materials for Oral TPOXX® Manufacturing Totaling $11 Million
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of an option under BARDA contract HHSO100201800019C (“2018 BARDA Contract”) worth a total...
Feb 21, 2019 07:30 am ET
SIGA to Present at the 8th Annual SVB Leerink Global Healthcare Conference on March 1, 2019
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the 8th Annual SVB Leerink...
Nov 15, 2018 08:15 am ET
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of NeuroMetrix, Inc. (NASDAQ:NURO), Sunesis Pharmaceuticals, Inc....
Nov 01, 2018 07:30 am ET
SIGA Announces Priority Review Voucher Transaction Totaling $80 Million
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV)...
Oct 09, 2018 12:00 pm ET
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic...
Oct 04, 2018 07:30 am ET
SIGA Enters into Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Disease to Evaluate the Efficacy of TPOXX® as a Post-Exposure Prophylactic for S
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States...
Sep 27, 2018 07:30 am ET
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global...
Sep 17, 2018 07:30 am ET
SIGA Technologies to Host Business Update Webcast on September 27, 2018
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on...
Sep 13, 2018 04:01 pm ET
SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, September 14, 2018....
Sep 10, 2018 05:50 pm ET
SIGA Technologies Awarded BARDA Contract for TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority...
Jul 13, 2018 03:47 pm ET
U.S. Food and Drug Administration Approves SIGA Technologies’ TPOXX® (tecovirimat) for the Treatment of Smallpox
SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment...
Jul 05, 2018 07:30 am ET
Pivotal Trial Data for SIGA Technologies’ Oral TPOXX® Published in the New England Journal of Medicine
SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, which comprises countermeasures for biological, chemical, radiological and nuclear attacks as well as vaccines and...
May 31, 2018 07:30 am ET
SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018
SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Jefferies Global...
May 01, 2018 04:03 pm ET
SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX®
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced a favorable outcome of...
May 01, 2018 07:05 am ET
SIGA Technologies Stock Trading Halted Today; FDA Advisory Committee is Scheduled to Review New Drug Application of TPOXX®
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Nasdaq has halted...
Mar 20, 2018 10:15 am ET
SIGA Technologies Announces Relisting on Nasdaq
Company Also Provides Milestone Updates
Mar 20, 2018 07:30 am ET
SIGA Technologies Announces Relisting on Nasdaq
Company Also Provides Milestone Updates
Feb 07, 2018 07:30 am ET
Dec 11, 2017 07:30 am ET
May 31, 2017 04:05 pm ET
SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017
NEW YORK, May 31, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 1:30 pm ET on Friday, June 9, 2017 in New York. Dr. Gomez will provide a corporate update and discuss the company’s lead investigational product TPOXX®, an antiviral drug targeting the treatment of orthopoxvirus infections, including smallpox....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.